• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LENZ Therapeutics, Inc. - Common Stock (NQ:LENZ)

5.790 +0.110 (+1.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about LENZ Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand
June 24, 2026
Exclusive license and commercialization agreement includes a significant profit share of gross margin from product sales in addition to an upfront license payment to LENZ 
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
June 07, 2026
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
Alpha Wave Global Reduces RadNet Stake, According to Recent SEC Filing ↗
June 02, 2026
RadNet runs a large outpatient imaging network and is building DeepHealth, its AI radiology platform. The upside is clearer if advanced imaging growth and digital health expansion can develop without... 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
LENZ Therapeutics (NASDAQ:LENZ) Q1 Report Shows Revenue Beat But Deepening Losses Sink Stock ↗
May 11, 2026
Via Chartmill
LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q4 Revenue Miss and Wider Loss Following VIZZ Launch ↗
March 24, 2026
Via Chartmill
News headline image
Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing ↗
May 27, 2026
COPT Defense Properties serves defense and intelligence tenants near secure government hubs. Investors will be closely watching whether that niche can keep supporting growth while much of the office... 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
LENZ Therapeutics to Participate in Upcoming Investor Conferences
May 26, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics Q1 Earnings Call Highlights ↗
May 11, 2026
LENZ Therapeutics (NASDAQ:LENZ) reported first-quarter 2026 results that showed continued prescription growth for its presbyopia eye drop VIZZ, while management acknowledged that new patient adoption... 
Via MarketBeat
Topics Earnings
News headline image
Lenz (LENZ) Q1 2026 Earnings Call Transcript ↗
May 11, 2026
Lenz (LENZ) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 11, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
April 20, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week ↗
March 27, 2026
It failed to meet expectations for its final quarter of 2025. 
Via The Motley Fool
News headline image
Why Lenz Therapeutics Stock Crashed Today ↗
March 24, 2026
Is it time to throw away your reading glasses? Maybe not just yet. 
Via The Motley Fool
News headline image
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
March 24, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings ↗
March 23, 2026
LENZ Therapeutics (NASDAQ:LENZ) to release Q4 earnings on 3/24. Analysts expect loss of 90 cents/share. Stock gained 5% on Monday. Analyst ratings and accuracy rates available on Benzinga. 
Via Benzinga
News headline image
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
March 17, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia
March 10, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics to Present at Upcoming Investor Conferences
February 23, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
January 20, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
January 14, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
January 13, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
January 07, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
January 06, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
January 05, 2026
Exclusive distribution agreement includes revenue sharing in addition to upfront and milestone payments to LENZ 
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
December 30, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
December 01, 2025
Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-U.S. regulatory submission for VIZZ 
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics to Present at Upcoming Investor Conferences
November 25, 2025
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
November 05, 2025
 
Via Benzinga
News headline image
LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q3 2025 Revenue Beat and Progress on VIZZ Launch ↗
November 05, 2025
LENZ Therapeutics Q3 2025 results show an 80% revenue beat and narrower loss as it launches its new FDA-approved vision treatment, VIZZ™. 
Via Chartmill
News headline image
LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 05, 2025
From LENZ Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap